Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cori Passer

Allergy & Immunology Overland Park, KS Medical Doctor

NPI 1902902497 CMS profile 177698

10787 Nall Ave, Suite 200, Overland Park, KS 66211

Open in the dashboard

General payments

$13,582

615 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cori Passer of Overland Park, KS is reported in the CMS Open Payments database as having received $13,582 across 615 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,433 143
2024 General $2,513 116
2023 General $2,455 120
2022 General $2,118 112
2021 General $1,093 34
2020 General $342 13
2019 General $1,627 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cori Passer
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Cori Passer were reported at $3,433. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Cori Passer Allergy & Immunology median Middle half National median
2019 $1,627 $594 $163–$1,512 $163
2020 $342 $426 $106–$1,233 $114
2021 $1,093 $638 $157–$1,708 $132
2022 $2,118 $790 $205–$1,961 $149
2023 $2,455 $852 $220–$2,147 $160
2024 $2,513 $865 $203–$2,267 $164
2025 $3,433 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,693 83 payments
  2. Regeneron Healthcare Solutions, Inc. $1,611 56 payments
  3. GlaxoSmithKline, LLC. $1,216 71 payments
  4. Genzyme Corporation $1,129 29 payments
  5. Genentech USA, Inc. $1,106 55 payments
  6. Novartis Pharmaceuticals Corporation $895 32 payments
  7. Pfizer Inc. $532 23 payments
  8. AbbVie, Inc. $509 41 payments
  9. Hospira, Inc. $474 32 payments
  10. Amgen Inc. $473 19 payments
  11. Other $3,945 174 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,367 610 payments
  2. Education $156 2 payments
  3. Consulting Fee $58 3 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Inflammation And Immunology $1,338 45 payments
  2. Xolair $1,106 55 payments
  3. DUPIXENT Immunology $849 30 payments
  4. NUCALA $546 30 payments
  5. CUTAQUIG $502 35 payments
  6. FASENRA $491 25 payments
  7. PANZYGA $470 33 payments
  8. TEZSPIRE Respiratory $464 19 payments
  9. TEZSPIRE Inflammation $450 18 payments
  10. OCTAGAM IMMUNE GLOBULIN (HUMAN) $449 31 payments
  11. Other $7,663 374 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

2,220

Median for Allergy/ Immunology: 449

Drug cost

$305,451

Median for Allergy/ Immunology: $169,700

Branded share of claims

33.2%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 137 $106,347
Breo Ellipta Fluticasone/Vilanterol Brand 79 $41,613
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 35 $32,531
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 102 $22,447
Symbicort Budesonide/Formoterol Fumarate Brand 47 $15,316
Advair Hfa Fluticasone Propion/Salmeterol Brand 31 $14,907
Azelastine Hcl Generic 245 $9,748
Wixela Inhub Fluticasone Propion/Salmeterol Brand 38 $7,831
Ipratropium Bromide Generic 200 $7,466
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 37 $7,376

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$360,627

Of which drugs: $290,048

Medicare patients

356

Average age 73

Services billed

7,893

254 women, 102 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Arthritis 50%
Depression 23%
Osteoporosis 22%
Diabetes 21%
Ischemic heart disease 21%
Chronic kidney disease 14%
Cancer 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, benralizumab, 1 mg J0517 Office 17 1,380 $180,988
Injection, omalizumab, 5 mg J2357 Office 16 3,540 $105,938
Vaccine for influenza for injection into muscle 90662 Office 30 30 $2,058

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $293
  • GENZYME CORPORATION $113
$406 — —
XOLAIR
  • Genentech USA, Inc. $148
  • Novartis Pharmaceuticals Corporation $99
$248 — 3,540
TEZSPIRE
  • Amgen Inc. $84
  • AstraZeneca Pharmaceuticals LP $81
$165 — —
Xhance
  • OptiNose US, Inc. $155
$155 — —
RUCONEST
  • Pharming Healthcare, Inc. $112
$112 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

615 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record